证券之星消息，1月29日生物制品板块较上一交易日下跌1.3%，华兰疫苗领跌。当日上证指数报收于 4157.98，上涨0.16%。深证成指报收于14300.08，下跌0.3%。生物制品板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 002880 | 卫光生物 | 30.07 | 4.59% | 8.81万 | | 2.66亿 | | 000661 | 长春高新 | 98.30 | 0.92% | 6.47万 | | 6.29亿 | | 300294 | 博雅生物 | 23.15 | 0.92% | 6.32万 | | 1.46亿 | | 300122 | 智飞生物 | 17.99 | 0.73% | - 43.69万 | | 7.78亿 | | 000403 | 派林生物 | 13.86 | 0.51% | 8.83万 | | 1.22亿 | | 600161 | 天坛生物 | 16.79 | 0.42% | 15.16万 | | 2.53亿 | | 6002 ...

Group 1 - The biopharmaceutical sector increased by 0.19% on January 21, with Nearshore Protein leading the gains [1] - The Shanghai Composite Index closed at 4116.94, up 0.08%, while the Shenzhen Component Index closed at 14255.12, up 0.7% [1] - Key stocks in the biopharmaceutical sector showed significant price increases, with Nearshore Protein rising by 6.37% to a closing price of 48.76 [1] Group 2 - The biopharmaceutical sector experienced a net inflow of 77.04 million yuan from institutional investors, while retail investors saw a net outflow of 284 million yuan [2] - Major stocks like Watson Bio and Ganli Pharmaceutical attracted significant institutional investment, with net inflows of 64.45 million yuan and 55.25 million yuan, respectively [3] - Retail investors showed a negative trend in several stocks, with Watson Bio and Ganli Pharmaceutical experiencing net outflows of 33.30 million yuan and 39.14 million yuan, respectively [3]

国药集团旗下天坛生物（600161.SH）近日完成核心人事调整。公司公告显示，因工作调整，原董事长 杨汇川辞去董事长、董事会战略与投资委员会主任委员等职务，仍继续担任第九届董事会董事、总经理 职务。 与此同时，天坛生物召开董事会，选举梁红军出任第九届董事会董事长，并当选为董事会战略与投资委 员会委员、提名委员会委员，同时兼任战略与投资委员会主任委员。 根据公开信息，杨汇川于2022年底接任天坛生物董事长一职，任职期间公司业绩实现稳步增长：2023 年、2024年分别实现营业收入51.8亿元、60.32亿元，同比增幅为21.57%、16.44%；归母净利润分别达 11.1亿元、15.49亿元，同比涨幅为25.99%、39.58%。不过2025年以来，天坛生物出现"增收不增利"的 业绩波动。 有业内人士向21世纪经济报道记者分析，此次人事更替背后，是我国血液制品行业近年业绩分化加剧、 市场竞争持续升级的行业态势。作为行业龙头企业，天坛生物的人事调整或为适应市场变化的战略布 局，国药集团亦有望借此进一步巩固行业地位，在血制行业存量博弈中寻求突破。 角色重构谋破局 此次人事调整中的杨汇川与梁红军，均为深耕国药体系多年 ...

Core Viewpoint - Tian Tan Biological, a subsidiary of China National Pharmaceutical Group, has undergone a significant personnel adjustment with the resignation of Chairman Yang Huichuan and the appointment of Liang Hongjun as the new chairman, indicating a strategic response to the competitive landscape in the blood products industry [1][3][4]. Company Summary - Yang Huichuan, who took over as chairman at the end of 2022, led the company to steady revenue growth, achieving operating revenues of 5.18 billion yuan and 6.032 billion yuan in 2023 and 2024, respectively, with year-on-year growth rates of 21.57% and 16.44% [3]. - The company reported net profits of 1.11 billion yuan and 1.549 billion yuan for the same years, with increases of 25.99% and 39.58% [3]. - However, since 2025, Tian Tan Biological has experienced fluctuations in performance, characterized by "increased revenue without increased profit" [3][5]. Personnel Changes - The new chairman, Liang Hongjun, has extensive experience within the China National Pharmaceutical Group and a strong financial background, which is seen as crucial for addressing the company's current need for cost control and profit stabilization [4][5]. - The dual leadership structure, with Yang remaining as general manager, aims to combine financial oversight with operational expertise [5]. Industry Context - The blood products industry in China has seen increasing performance disparities among companies, with Tian Tan Biological facing intensified competition [3][7]. - The industry has been experiencing a slowdown in growth, with some companies reporting significant revenue declines, while others, including Tian Tan Biological, have shown mixed results [7][8]. - The market is currently characterized by price declines and cash flow pressures, leading to concerns about the sustainability of profits in the short term [8]. Future Outlook - The focus for Tian Tan Biological in 2026 is expected to shift from expansion to improving quality and efficiency, emphasizing cost control and profit stability [6][9]. - The ongoing adjustments in leadership and strategy will be critical for the company to navigate the evolving market dynamics and competitive pressures [9].

Key Points - China Metallurgical Group Corporation (China MCC) expects a decline of over 50% in net profit attributable to shareholders in 2025 due to losses in the real estate sector and increased asset impairment provisions [1] - JAC Motors anticipates a net loss of approximately 1.68 billion yuan in 2025, although this represents a reduction in losses compared to the previous year [2] - Northern Rare Earth forecasts a net profit increase of 116.67% to 134.60% in 2025, driven by improved sales and production efficiency in rare earth products [3] - Shenghong Technology projects a net profit increase of 260.35% to 295% in 2025, attributed to the growing demand for AI infrastructure and high-end products [4] - Lanke Technology expects a net profit increase of 52.29% to 66.46% in 2025, benefiting from strong demand in the AI industry [7] - Aiwai Electronics anticipates a net profit increase of 17.70% to 29.47% in 2025, focusing on high-value chip solutions [25] - Longxin General expects a net profit increase of 47.15% to 60.53% in 2025, driven by steady growth in its core motorcycle and general machinery businesses [28] - China One Heavy Industry predicts a net loss of 310 million to 460 million yuan in 2025, although this represents a significant reduction from the previous year's loss [35] - Kunda Technology expects a net loss of 1.2 billion to 1.5 billion yuan in 2025, impacted by industry supply-demand imbalances [34] - Daqing Energy anticipates a net loss of 1 billion to 1.3 billion yuan in 2025, although this reflects a narrowing of losses compared to the previous year [42]

Core Viewpoint - On January 16, TianTan Biological announced that former chairman Yang Huichuan resigned from multiple positions due to work adjustments, while still retaining his role as a director and general manager of the company [1] Group 1 - Yang Huichuan submitted his resignation from the positions of chairman and chairman of the strategy and investment committee [1] - After resigning from these positions, Yang Huichuan continues to hold 46,800 shares in the company, representing 0.0024% of the total shareholding [1]

证券代码：600161 证券简称：天坛生物 公告编号：2026-002 北京天坛生物制品股份有限公司董事长离任公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 北京天坛生物制品股份有限公司（以下简称"公司"）董事会收到公司董事 长杨汇川先生递交的书面辞职报告。现将有关情况公告如下： 一、提前离任的基本情况 | 是否继 | 是 | 否 | 存 | 原定 | 离 | 续在上 | | | | | | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 在 | 未 | 履 | 姓 | 离任 | 任期 | 任 | 市公司 | 具体 | 离任职务 | 行 | 完 | 毕 | | | | | | | | | | | 名 | 时间 | 到期 | 原 | 及其控 | 职务 | 的 | ...

证券代码：600161 证券简称：天坛生物 公告编号：2026-001 本次会议是否有否决议案：无 一、会议召开和出席情况 （一）股东会召开的时间：2026 年 1 月 16 日 （二）股东会召开的地点：北京市朝阳区双桥路乙 2 号院会议室 （三）出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： 北京天坛生物制品股份有限公司 2026年第一次临时股东会决议公告 | 1、出席会议的股东和代理人人数 | 798 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 1,032,514,086 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股份 | 52.2164 | | 总数的比例（%） | | 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议由董事会召集，董事长杨汇川先生主持，会议采用现场投票与网络投 票相结合的方式对提案进行表决，符合《公司法》及《公司章程》的规定。本次会 议经北京市嘉源律师事务所律师出席见证，出具《法律意见书》，会议程序合法， ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 北京天坛生物制品股份有限公司（以下简称"公司"）第九届董事会第二十九次 会议于 2026 年 1 月 6 日发出会议通知，于 2026 年 1 月 16 日以现场与视频结合方式 在北京市朝阳区双桥路乙 2 号院办公楼二层第六会议室召开。会议由董事长梁红军先 生主持，会议应到董事九人，实到董事八人，董事孙京林先生因公务未能出席会议， 委托董事杨汇川先生代为表决。会议出席人数符合《公司法》及《公司章程》规定的 有效人数，会议按预定程序审议了议程中全部议案。会议做出决议如下： 证券代码：600161 证券简称：天坛生物 公告编号：2026-003 北京天坛生物制品股份有限公司 第九届董事会第二十九次会议决议公告 表决结果：9 票同意，0 票反对，0 票弃权。 三、审议通过《关于修订<股权投资管理办法>的议案》 同意修订后的《北京天坛生物制品股份有限公司股权投资管理办法》。 表决结果：9 票同意，0 票反对，0 票弃权。 特此公告。 北京天坛生物制品股份有限公司 2026 年 1 月 1 ...

Group 1 - The company TianTan Biological announced the resignation of its chairman Yang Huichuan due to work adjustments, while he will continue to serve as a board member and general manager [1] - Yang Huichuan has stepped down from multiple positions including chairman, head of the strategic and investment committee, and member of the performance assessment and compensation committee [1] - The resignation is effective immediately upon delivery to the company's board of directors [1] Group 2 - The Ministry of Finance has imposed maximum penalties on a company for concealing key audit work papers and refusing to cooperate with investigations regarding financial misconduct [1]